Stock A288330 BRIDGE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Bridge Biotherapeutics, Inc. Stock

Equities

A288330

KR7288330004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
2,280 KRW +1.11% Intraday chart for Bridge Biotherapeutics, Inc. +5.80% -30.59%
Mar. 28 Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade CI
Mar. 26 Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology CI

Financials

Sales 2022 3.02B 2.21M Sales 2023 100M 73.1K Capitalization 73.11B 53.44M
Net income 2022 -41.7B -30.48M Net income 2023 -42.32B -30.94M EV / Sales 2022 60.4 x
Net cash position 2022 48.29B 35.3M Net cash position 2023 16.64B 12.16M EV / Sales 2023 565 x
P/E ratio 2022
-5.52 x
P/E ratio 2023
-1.6 x
Employees 43
Yield 2022 *
-
Yield 2023
-
Free-Float 78.86%
More Fundamentals * Assessed data

Chart Bridge Biotherapeutics, Inc.

Dynamic Chart

Latest news about Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade CI
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding CI
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy CI
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC CI
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis CI
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting CI
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis CI
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401 CI
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis CI
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022 CI
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877 CI
More news

Press releases Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics to Present at the 2023 BIO International Convention AQ
Bridge Biotherapeutics announces preclinical study of self-discovered 4th generation lung cancer targeted therapy at AACR conference in the US AQ
Bridge Biotherapeutics : Material Management Information related to Judgment of Investment (US FDA approval of BBT-877 phase 2 clinical trial plan for the treatment of Idiopathic Pulmonary Fibrosis (IPF)) PU
Bridge Biotherapeutics : Organization of Investor Relations Event PU
Bridge Biotherapeutics : Results of issuance(Voluntary Disclosure) (제3자배정-전환우선주) PU
More press releases

Quotes and Performance

1 day+1.11%
1 week+5.80%
Current month-1.51%
1 month+4.11%
3 months-33.43%
6 months-14.77%
Current year-30.59%
More quotes

Highs and lows

1 week
2 100.00
Extreme 2100
2 345.00
1 month
1 998.00
Extreme 1998
2 435.00
Current year
1 998.00
Extreme 1998
6 600.00
1 year
1 998.00
Extreme 1998
8 150.00
3 years
1 998.00
Extreme 1998
16 250.00
5 years
1 998.00
Extreme 1998
21 633.33
10 years
1 998.00
Extreme 1998
21 633.33
More quotes

Managers and Directors - Bridge Biotherapeutics, Inc.

Managers TitleAgeSince
Jeong-Gyu Lee FOU
 Founder 56 15-09-16
Sujin Jung COO
 Chief Operating Officer - -
Sang-Wook Kang CTO
 Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Seung-Yeob Baek BRD
 Director/Board Member 64 -
Seung-Hoon Lee BRD
 Director/Board Member 62 -
Jeong-Gyu Lee FOU
 Founder 56 15-09-16
More insiders

Quotes

Date Price Change Volume
24-06-05 2,280 +1.11% 94,450
24-06-04 2,255 -1.53% 78,031
24-06-03 2,290 -1.08% 128,185
24-05-31 2,315 +10.24% 186,578
24-05-30 2,100 -2.55% 103,259

End-of-day quote Korea S.E., June 04, 2024

More quotes

Company Profile

Bridge Biotherapeutics, Inc. is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The products mainly consist of ulcerative colitis medicine BBT-401, autoxin inhibitor BBT-877, non-small cell lung cancer medicine BBT-176, and others. The Company is also involved in the manufacture of basic pharmaceuticals and biologicals.
Sector
Biotechnology & Medical Research
Calendar
2024-08-08 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BRIDGE BIOTHERAPEUTICS, INC. Stock Bridge Biotherapeutics, Inc.
-30.59% 40.15M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 123B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.53% 107B
BIONTECH SE Stock BioNTech SE
-2.88% 24.01B
ARGENX SE Stock argenx SE
+2.18% 22.59B
GENMAB A/S Stock Genmab A/S
-10.09% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.04% 16.84B
BEIGENE, LTD. Stock BeiGene, Ltd.
-11.83% 16.23B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.46% 13.43B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.22% 11.32B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A288330 Stock